Last edition
News about "Paul Richardson"
Bristol Myers Squibb reported Phase 3 SUCCESSOR-2 results showing that mezigdomide reduced the risk of disease progression or death by more than 50% versus standard of care in relapsed or refractory multiple myeloma, marking the first successful Phase 3 CELMoD trial presented at ASCO 2026.
Paul Richardson | 30/05/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members